These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 8706029

  • 1. An uncertain role for p53 gene alterations in human prostate cancers.
    Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB.
    Cancer Res; 1996 Aug 15; 56(16):3814-22. PubMed ID: 8706029
    [Abstract] [Full Text] [Related]

  • 2. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL, Dean RC, Zhang W, Young D, Sesterhenn IA, Shanmugam N, McLeod DG, Moul JW, Srivastava S.
    Prostate Cancer Prostatic Dis; 2003 Aug 15; 6(4):281-5. PubMed ID: 14663467
    [Abstract] [Full Text] [Related]

  • 3. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss.
    Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT.
    Cancer Res; 1996 Oct 01; 56(19):4387-90. PubMed ID: 8813131
    [Abstract] [Full Text] [Related]

  • 4. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas.
    Wagata T, Shibagaki I, Imamura M, Shimada Y, Toguchida J, Yandell DW, Ikenaga M, Tobe T, Ishizaki K.
    Cancer Res; 1993 Feb 15; 53(4):846-50. PubMed ID: 8094033
    [Abstract] [Full Text] [Related]

  • 5. Chromosome 17p deletions and p53 mutations in renal cell carcinoma.
    Reiter RE, Anglard P, Liu S, Gnarra JR, Linehan WM.
    Cancer Res; 1993 Jul 01; 53(13):3092-7. PubMed ID: 8319216
    [Abstract] [Full Text] [Related]

  • 6. Association of p53 mutations with metastatic prostate cancer.
    Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC.
    Clin Cancer Res; 1995 Oct 01; 1(10):1111-8. PubMed ID: 9815901
    [Abstract] [Full Text] [Related]

  • 7. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer.
    Massenkeil G, Oberhuber H, Hailemariam S, Sulser T, Diener PA, Bannwart F, Schäfer R, Schwarte-Waldhoff I.
    Anticancer Res; 1994 Oct 01; 14(6B):2785-90. PubMed ID: 7872719
    [Abstract] [Full Text] [Related]

  • 8. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma.
    Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ.
    J Urol; 1996 May 01; 155(5):1685-92. PubMed ID: 8627854
    [Abstract] [Full Text] [Related]

  • 9. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer.
    Dalbagni G, Presti JC, Reuter VE, Zhang ZF, Sarkis AS, Fair WR, Cordon-Cardo C.
    Diagn Mol Pathol; 1993 Mar 01; 2(1):4-13. PubMed ID: 7904525
    [Abstract] [Full Text] [Related]

  • 10. Allelic loss of chromosome 17p, mutation of the p53 gene, and microsatellite instability in right- and left-sided colorectal cancer.
    Watatani M, Yoshida T, Kuroda K, Ieda S, Yasutomi M.
    Cancer; 1996 Apr 15; 77(8 Suppl):1688-93. PubMed ID: 8608563
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas.
    Yamaguchi T, Toguchida J, Wadayama B, Kanoe H, Nakayama T, Ishizaki K, Ikenaga M, Kotoura Y, Sasaki MS.
    Anticancer Res; 1996 Apr 15; 16(4A):2009-15. PubMed ID: 8712735
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T, Tokuchi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S, Ishikawa Y, Tsuchiya S, Nakagawa K, Hayashi J, Tsuchiya E.
    Cancer Res; 1999 Nov 01; 59(21):5572-7. PubMed ID: 10554037
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Loss of heterozygosity and overexpression of the p53 gene in ovarian carcinoma.
    Frank TS, Bartos RE, Haefner HK, Roberts JA, Wilson MD, Hubbell GP.
    Mod Pathol; 1994 Jan 01; 7(1):3-8. PubMed ID: 7909153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.